BIOINDUSTRY ETHICS -- BIOINDUSTRY ETHICS -- Contents -- Research Team -- Preface -- Acknowledgments -- Introduction -- ETHICAL ISSUES CONFRONTING BIOSCIENCE COMPANIES -- WHY SHOULD BIOSCIENCE FIRMS CARE ABOUT ETHICS? -- ETHICISTS AND THE BIOSCIENCE INDUSTRY -- A NEW APPROACH: BIOSCIENCE BUSINESS ETHICS -- STRUCTURE OF THE BOOK -- Merck: Staying the Course -- INTRODUCTION -- FOCUSING ON PATIENTS AND THE LONG TERM -- ETHICS RESOURCE CENTERS -- INTERNAL ETHICAL PRACTICES -- ASSESSING THE IMPACT -- BENEFITS OF AN ETHICAL APPROACH -- ETHICAL ISSUES -- DRUG PRICING, ACCESS, AND INTELLECTUAL PROPERTY -- CLINICAL TRIALS AND PUBLICATION OF RESULTS -- WHAT DRUGS TO DEVELOP -- CHALLENGES FOR THE FUTURE -- Genzyme: Putting Patients First -- INTRODUCTION -- PUTTING THE PATIENT FIRST: GENZYMEÌS APPROACH TO ETHICAL ISSUES -- ETHICAL ISSUES -- ETHICAL MECHANISMS -- SUSTAINING THE GENZYME CULTURE -- CONCLUSION -- Millennium pharmaceuticals, Inc.: Creating and Sustaining Corporate Values -- INTRODUCTION -- MILLENNIUM PHARMACEUTICALS INC. -- INSTITUTIONALIZING CORE VALUES AND ETHICS -- ETHICS EDUCATION PROGRAMS -- IMPACT OF INSTITUTIONALIZATION OF VALUES AND ETHICS -- PRESERVING A FOCUS ON CORE VALUES -- THE FUTURE -- Maxim Pharmaceuticals (A): Internal and External Dialogues -- AN UNUSUAL BIOTECH LEADER -- THE IMPACT OF BUSINESS ETHICS IN THE BIOSCIENCE INDUSTRY -- COMPANY HISTORY -- EMBEDDING CORE VALUES -- MECHANISMS FOR EMBEDDING CORE VALUES -- BUILDING A SUCCESSFUL GLOBAL BOARD -- ANNUAL STRATEGIC RETREAT -- DEALING WITH ETHICAL ISSUES -- MAXIM PHARMACEUTICALS (B) -- Diversa Inc.: Ethical Issues in Bioprospecting Partnerships -- FROM BIOPIRACY TO BIOPROSPECTING -- THE COMPANY -- THE CONTEXT FOR BIOPROSPECTING PARTNERSHIPS -- DIVERSAÌS BIODIVERSITY COLLABORATIONS -- PROCESS FOR ESTABLISHING AND IMPLEMENTING COLLABORATIVE AGREEMENTS -- ETHICAL DECISION MAKING.

TOWARD THE FUTURE -- DIVERSA INC. (B) -- DIVERSA INC. (C) -- DIVERSA INC. (D) -- Pipeline Biotech A/S: Competing Regulatory Regimes for Laboratory Animal Experiments -- INTRODUCTION -- COMPANY HISTORY -- BUSINESS MODEL AND ETHICAL APPROACH -- EMPOWERING THE WORKFORCE -- ETHICAL ISSUES AT PIPELINE -- CONCLUSION -- TGN Biotech: A Start-Up with Ethical Roots -- WHAT NOW? -- TGN BIOTECH -- TGNÌS MARKET -- SEMENESISTM -- WHY PIGS AND WHY SEMEN? -- THE ETHICAL ISSUES -- MECHANISMS FOR A TRANSPARENT PROCESS -- FUTURE POSSIBILITIES -- WHAT NEXT? -- Interleukin Genetics and Alticor: An Unlikely Partnership -- INTRODUCTION -- COMPANY ORIGINS -- EXPLORING THE ETHICS OF GENETIC TESTING -- FAILED EFFORTS TO BUILD A PERSONALIZED MEDICINE BUSINESS -- PUTTING ETHICS EXPERTS IN CHARGE -- APPROACH TO ETHICAL ISSUES -- PROPOSED ALTICOR DEAL -- INTERLEUKIN GENETICS AND ALTICOR: AN UNUSUAL PARTNERSHIP -- CREATING AN ETHICAL APPROACH TO NUTRIGENOMICS -- Sciona Ltd.: A Pioneer in Nutrigenomics: The Path to Consumer Acceptance -- INTRODUCTION -- BACKGROUND -- PRODUCT LAUNCH -- ETHICAL CONSIDERATIONS -- THE CASE FOR ETHICS -- APPLICATION TO THE HUMAN GENETICS COMMISSION -- PUBLIC OPPOSITION -- RESULTS -- THE HGC RECOMMENDATIONS -- TOWARD THE FUTURE -- Affymetrix, Inc.: Using Corporate Ethics Advice -- INTRODUCTION -- DNA CHIP TECHNOLOGY -- APPLICATIONS OF DNA CHIPS -- COMPANY HISTORY -- AFFYMETRIX ETHICS ADVISORY COMMITTEE FORMATION -- OPERATION OF THE ETHICS COMMITTEE -- ADVICE PROVIDED BY THE ETHICS ADVISORY COMMITTEE -- THE FUTURE OF ETHICS AT AFFYMETRIX -- CONCLUSION -- PharmaSNPs Inc.: Creating an Ethics Advisory Board -- INTRODUCTION -- THE COMPANY -- HOW A PHARMACOGENOMICS STUDY WORKS -- CREATING AND IMPLEMENTING AN EAB -- THE EAB PROCESS -- ROLE OF THE COMPANY -- EAB-COMPANY RELATIONSHIP -- EXAMPLES OF ETHICAL ISSUES -- LESSONS LEARNED -- CONCLUSION.

CASE (B): POSTSCRIPT -- Monsanto Company: Bio- Agriculture Pioneer -- A LIGHTNING ROD FOR ETHICAL CONTROVERSIES -- THE POLARIZED DEBATE -- MONSANTO UNDER ATTACK -- MONSANTO COMPANY (B) -- THE NEW MONSANTO -- THE IMPACT OF THE PLEDGE ON MONSANTO -- THE IMPACT OF THE PLEDGE EXTERNALLY -- A MORE NUANCED PUBLIC DEBATE -- MEASURING THE EFFECTIVENESS OF THE PLEDGE -- TOWARD THE FUTURE -- Novo Nordisk: The Triple Bottom Line -- INTRODUCTION -- THE COMPANY -- MAKING THE CASE FOR ACTING RESPONSIBLY -- THE TRIPLE BOTTOM LINE -- FUTURE CHALLENGES -- Conclusion: Lessons for Companies and Future Issues -- WHAT ETHICAL ISSUES DO BIOSCIENCE COMPANIES FACE? -- ISSUE 1: FINANCIAL PRESSURES -- ISSUE 2: DEVELOPING CUTTING-EDGE TECHNOLOGIES -- ISSUE 3: RESEARCH ETHICS -- ISSUE 4: REGULATORY GUIDELINES INSUFFICIENT -- ISSUE 5: MARKETING AND DELIVERY OF PRODUCTS -- ISSUE 6: VALUE, PRICING, AND ACCESS TO PRODUCTS -- ISSUE 7: DOING BUSINESS GLOBALLY -- ISSUE 8: CONFLICTS OF INTEREST -- ISSUE 9: CORPORATE AND SOCIAL RESPONSIBILITY -- ISSUE 10: BUSINESS ETHICS AND GOOD GOVERNANCE -- BUILDING AN ETHICAL DECISION MAKING PROCESS -- KEY FUTURE TRENDS -- CONCLUSION -- Index.